These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10770564)

  • 1. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
    Egawa S; Takashima R; Matsumoto K; Mizoguchi H; Kuwao S; Baba S
    Jpn J Clin Oncol; 2000 Jan; 30(1):21-6. PubMed ID: 10770564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T; Campbell J; Bryant C; Lynch W
    Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
    de Leval J; Boca P; Yousef E; Nicolas H; Jeukenne M; Seidel L; Bouffioux C; Coppens L; Bonnet P; Andrianne R; Wlatregny D
    Clin Prostate Cancer; 2002 Dec; 1(3):163-71. PubMed ID: 15046691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
    Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
    J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.
    Grossfeld GD; Chaudhary UB; Reese DM; Carroll PR; Small EJ
    Urology; 2001 Aug; 58(2):240-5. PubMed ID: 11489710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
    Diamond TH; Winters J; Smith A; De Souza P; Kersley JH; Lynch WJ; Bryant C
    Cancer; 2001 Sep; 92(6):1444-50. PubMed ID: 11745221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM
    Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
    Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
    Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
    Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.
    Higano CS; Ellis W; Russell K; Lange PH
    Urology; 1996 Nov; 48(5):800-4. PubMed ID: 8911533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.